EGLN3 and chronic kidney disease: HIF‐PHIs are an emerging new class of agents that stimulate erythropoiesis through the inhibition of HIF‐prolyl hydroxylase enzymes (PHD1, PHD2, and PHD3), and are being investigated for the treatment of anemia in chronic kidney disease (CKD).4, 5